rs553752236

Variant summary

Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_ModerateBP6BS1BS2

The NM_000455.5(STK11):​c.1045G>A​(p.Glu349Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0000168 in 1,611,590 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E349A) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000039 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000014 ( 1 hom. )

Consequence

STK11
NM_000455.5 missense

Scores

1
2
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:5

Conservation

PhyloP100: 3.92

Publications

8 publications found
Variant links:
Genes affected
STK11 (HGNC:11389): (serine/threonine kinase 11) The protein encoded by this gene is a serine/threonine kinase that regulates cell polarity and energy metabolism and functions as a tumor suppressor. Mutations in this gene have been associated with the autosomal dominant Peutz-Jeghers syndrome, as well as with skin, pancreatic, and testicular cancers. [provided by RefSeq, May 2022]
STK11 Gene-Disease associations (from GenCC):
  • familial pancreatic carcinoma
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • Peutz-Jeghers syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Genomics England PanelApp, G2P
  • familial ovarian cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -11 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.09029716).
BP6
Variant 19-1223109-G-A is Benign according to our data. Variant chr19-1223109-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 127697.
BS1
Variant frequency is greater than expected in population amr. GnomAdExome4 allele frequency = 0.0000144 (21/1459294) while in subpopulation AMR AF = 0.000157 (7/44608). AF 95% confidence interval is 0.000073. There are 1 homozygotes in GnomAdExome4. There are 7 alleles in the male GnomAdExome4 subpopulation. Median coverage is 31. This position passed quality control check.
BS2
High AC in GnomAd4 at 6 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
STK11NM_000455.5 linkc.1045G>A p.Glu349Lys missense_variant Exon 8 of 10 ENST00000326873.12 NP_000446.1
STK11NM_001407255.1 linkc.1045G>A p.Glu349Lys missense_variant Exon 8 of 9 NP_001394184.1
STK11NR_176325.1 linkn.2312G>A non_coding_transcript_exon_variant Exon 9 of 11

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
STK11ENST00000326873.12 linkc.1045G>A p.Glu349Lys missense_variant Exon 8 of 10 1 NM_000455.5 ENSP00000324856.6
STK11ENST00000652231.1 linkc.1045G>A p.Glu349Lys missense_variant Exon 8 of 9 ENSP00000498804.1
STK11ENST00000585748.3 linkc.673G>A p.Glu225Lys missense_variant Exon 10 of 12 3 ENSP00000477641.2
STK11ENST00000593219.6 linkn.*870G>A non_coding_transcript_exon_variant Exon 9 of 11 3 ENSP00000466610.1
STK11ENST00000593219.6 linkn.*870G>A 3_prime_UTR_variant Exon 9 of 11 3 ENSP00000466610.1

Frequencies

GnomAD3 genomes
AF:
0.0000394
AC:
6
AN:
152178
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000724
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000491
AC:
12
AN:
244542
AF XY:
0.0000150
show subpopulations
Gnomad AFR exome
AF:
0.0000669
Gnomad AMR exome
AF:
0.000233
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000168
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000144
AC:
21
AN:
1459294
Hom.:
1
Cov.:
31
AF XY:
0.00000964
AC XY:
7
AN XY:
725782
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33466
American (AMR)
AF:
0.000157
AC:
7
AN:
44608
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26090
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39670
South Asian (SAS)
AF:
0.00
AC:
0
AN:
85934
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52054
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5764
European-Non Finnish (NFE)
AF:
0.0000117
AC:
13
AN:
1111394
Other (OTH)
AF:
0.00
AC:
0
AN:
60314
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.457
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000394
AC:
6
AN:
152296
Hom.:
0
Cov.:
33
AF XY:
0.0000403
AC XY:
3
AN XY:
74470
show subpopulations
African (AFR)
AF:
0.0000722
AC:
3
AN:
41566
American (AMR)
AF:
0.000131
AC:
2
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5176
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4818
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68028
Other (OTH)
AF:
0.00
AC:
0
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000130
Hom.:
0
Bravo
AF:
0.0000453
ExAC
AF:
0.0000332
AC:
4

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2
Oct 19, 2017
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is denoted STK11 c.1045G>A at the cDNA level, p.Glu349Lys (E349K) at the protein level, and results in the change of a Glutamic Acid to a Lysine (GAG>AAG). This variant has not, to our knowledge, been published in the literature as a germline variant. However, it has been reported as a somatic variant in an individual with medullary thyroid cancer and in an individual with cervical cancer (Ji 2015, Lou 2015). STK11 Glu349Lys was observed at an allele frequency of 0.041% (3/7388) in individuals of East Asian ancestry in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Glutamic Acid and Lysine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. STK11 Glu349Lys occurs at a position that is not conserved and is not located in a known functional domain. In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available information, it is unclear whether STK11 Glu349Lys is pathogenic or benign. We consider it to be a variant of uncertain significance.

Feb 18, 2020
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The STK11 c.1045G>A; p.Glu349Lys variant (rs553752236) has been reported in an individual with breast cancer but also in a healthy control (Momozawa 2018). This variant is reported in the ClinVar database (Variation ID: 127697). It is found in the general population with an overall allele frequency of 0.005% (13/275920 alleles, including 1 homozygote) in the Genome Aggregation Database. The glutamate at codon 349 is moderately conserved, but computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of this variant is uncertain at this time. REFERENCES Momozawa Y et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018 Oct 4;9(1):4083.

Hereditary cancer-predisposing syndrome Benign:2
Jun 21, 2021
Color Diagnostics, LLC DBA Color Health
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 16, 2018
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Peutz-Jeghers syndrome Benign:2
Jan 26, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jul 15, 2021
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Uncertain:1
Aug 08, 2016
St. Jude Molecular Pathology, St. Jude Children's Research Hospital
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not specified Benign:1
Nov 03, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The STK11 c.1045G>A (p.Glu349Lys) variant causes a missense change involving the alteration of a conserved nucleotide. 3/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 13/273218 control chromosomes in gnomAD at a frequency of 0.0000476, which is approximately 8 times the estimated maximal expected allele frequency of a pathogenic STK11 variant (0.0000063), suggesting this variant is likely a benign polymorphism. This variant was reported in one case of medullary thyroid cancer as a somatic variant (Ji_2015). Multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Taken together, this variant is classified as likely benign.

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.31
T
BayesDel_noAF
Benign
-0.39
CADD
Benign
19
DANN
Uncertain
0.97
DEOGEN2
Benign
0.32
T;D
Eigen
Benign
-0.61
Eigen_PC
Benign
-0.60
LIST_S2
Uncertain
0.87
D;D
M_CAP
Benign
0.034
D
MetaRNN
Benign
0.090
T;T
MetaSVM
Benign
-0.94
T
MutationAssessor
Benign
0.0
.;L
PhyloP100
3.9
PrimateAI
Benign
0.27
T
PROVEAN
Benign
0.0
.;N
Sift
Pathogenic
0.0
.;T
Sift4G
Benign
0.63
T;T
Vest4
0.25
ClinPred
0.032
T
GERP RS
2.8
PromoterAI
0.018
Neutral
Varity_R
0.099
gMVP
0.36
Mutation Taster
=96/4
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs553752236; hg19: chr19-1223108; API